Knight Therapeutics Inc
TSX:GUD
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.11
6.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one GUD stock under the Base Case scenario is 6.31 CAD. Compared to the current market price of 5.29 CAD, Knight Therapeutics Inc is Undervalued by 16%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Knight Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for GUD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Knight Therapeutics Inc
Balance Sheet Decomposition
Knight Therapeutics Inc
Current Assets | 397.6m |
Cash & Short-Term Investments | 172.3m |
Receivables | 103m |
Other Current Assets | 122.2m |
Non-Current Assets | 564.7m |
Long-Term Investments | 105.6m |
PP&E | 21.6m |
Intangibles | 364.5m |
Other Non-Current Assets | 73m |
Current Liabilities | 118.2m |
Accounts Payable | 86.6m |
Other Current Liabilities | 31.5m |
Non-Current Liabilities | 70.2m |
Long-Term Debt | 36.5m |
Other Non-Current Liabilities | 33.7m |
Earnings Waterfall
Knight Therapeutics Inc
Revenue
|
348.6m
CAD
|
Cost of Revenue
|
-180.4m
CAD
|
Gross Profit
|
168.3m
CAD
|
Operating Expenses
|
-167m
CAD
|
Operating Income
|
1.3m
CAD
|
Other Expenses
|
-32m
CAD
|
Net Income
|
-30.7m
CAD
|
Free Cash Flow Analysis
Knight Therapeutics Inc
CAD | |
Free Cash Flow | CAD |
GUD Profitability Score
Profitability Due Diligence
Knight Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Knight Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
GUD Solvency Score
Solvency Due Diligence
Knight Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Knight Therapeutics Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GUD Price Targets Summary
Knight Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GUD is 6.9 CAD with a low forecast of 6.16 CAD and a high forecast of 7.88 CAD.
Dividends
Current shareholder yield for GUD is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.
Contact
IPO
Employees
Officers
The intrinsic value of one GUD stock under the Base Case scenario is 6.31 CAD.
Compared to the current market price of 5.29 CAD, Knight Therapeutics Inc is Undervalued by 16%.